FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Silva Paul M							2. Issuer Name and Ticker or Trading Symbol VERTEX PHARMACEUTICALS INC / MA [VRTX]								all appli Directo	or (give title		son(s) to Iss 10% Ov Other (s	vner		
(Last) C/O VEH INCORP		3. Date of Earliest Transaction (Month/Day/Year) 10/25/2013									X Ollicer (give title Other (specify below) SVP & Corp Controller										
130 WAVERLY ST.							4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street) CAMBRIDGE MA 02139															X Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City) (State) (Zip)																					
		Tab	le I - N	lon-Deri	vative	Sec	uriti	ies Ad	quire	d, D	isposed o	of, or Bo	enefici	ally	Owned	ı					
Date				2. Transac Date (Month/Da		Execuear) if any		eemed ution Date, / th/Day/Year)		action (Instr.	4. Securities Acquired (AD Disposed Of (D) (Instr. 3					5. Amount of Securities Beneficially Owned Following		: Direct Indirect str. 4)	7. Nature of Indirect Beneficial Ownership		
								Code	v	Amount	(A) or (D)	Price		Reporte Transac (Instr. 3	tion(s)			(Instr. 4)			
Common Stock 10/25/20					2013	13		M		1,125	A	\$48.7	74	12	,875	D					
Common Stock 10/25/20					2013	13			S ⁽¹⁾		1,025	D	\$76.56	(2)(3)	11	,850		D			
Common Stock 10/25/20					2013	13			S ⁽¹⁾		100	D	\$78.2	29	11	,750		D			
Common Stock														169			I	401(k)			
		Т	Table II								posed of converti				wned						
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	if any		4. Transa Code (8)	ction	5. Number of			Exerc	cisable and	7. Title a Amount Securitie Underlyi	nd of s ng e Security	8. De Se	Price of erivative ecurity nstr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactic (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
					Code	v	(A)	(D)	Date Exercis	sable	Expiration Date	Title	Amoun or Numbe of Shares								
Stock Option (right to buy)	\$48.74	10/25/2013			M			1,125	(4))	07/24/2022	Common Stock	1,125		\$0.00	12,375	5	D			

Explanation of Responses:

- $1.\ Transaction\ made\ pursuant\ to\ Mr.\ Silva's\ company\ approved\ trading\ plan\ under\ Rule\ 10b5-1.$
- 2. Open market sales reported on this line occurred at a weighted average price of \$76.56 (range \$76.22 to \$76.97).
- 3. Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- 4. The option vests in 16 quarterly installments from 07/25/2012.

Remarks:

Kenneth L. Horton, Attorney-

10/29/2013

In-Fact ** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.